Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 4, Avril 2015
Page(s) 404 - 416
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153104015
Publié en ligne 8 mai 2015
  1. Dugue GP, Akemann W, Knopfel T. A comprehensive concept of optogenetics. Prog Brain Res 2012 ; 196 : 1–28. [CrossRef] [PubMed]
  2. Dugue GP, Tricoire L. Principes et applications de l’optogénétique en neuroscience. Med Sci (Paris) 2015 ; 31 : 291–303. [CrossRef] [EDP Sciences] [PubMed]
  3. Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annu Rev Neurosci 2011 ; 34 : 389–412. [CrossRef] [PubMed]
  4. Han MH, Friedman AK. Virogenetic and optogenetic mechanisms to define potential therapeutic targets in psychiatric disorders. Neuropharmacology 2012 ; 62 : 89–100. [CrossRef] [PubMed]
  5. Lozano AM, Lipsman N. Probing and regulating dysfunctional circuits using deep brain stimulation. Neuron 2013 ; 77 : 406–424. [CrossRef] [PubMed]
  6. Lipsman N, Giacobbe P, Lozano AM. Deep brain stimulation in obsessive-compulsive disorder: neurocircuitry and clinical experience. Handb Clin Neurol 2013 ; 116 : 245–250. [CrossRef] [PubMed]
  7. Sankar T, Lipsman N, Lozano AM. Deep brain stimulation for disorders of memory and cognition. Neurotherapeutics 2014 ; 11 : 527–534. [CrossRef]
  8. Lipsman N, Woodside DB, Lozano AM. Neurocircuitry of limbic dysfunction in anorexia nervosa. Cortex 2014 ; 62 : 109–118. [CrossRef] [PubMed]
  9. Mallet L, Schüpbach M, N’Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci USA 2007 ; 104 : 10661–10666. [CrossRef]
  10. Allen BD, Singer AC, Boyden ES. Principles of designing interpretable optogenetic behavior experiments. Learn Mem 2015 ; 22 : 232–238. [CrossRef] [PubMed]
  11. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 2011 ; 11 : 307–320. [CrossRef] [PubMed]
  12. Duale H, Kasparov S, Paton JF, Teschemacher AG. Differences in transductional tropism of adenoviral and lentiviral vectors in the rat brainstem. Exp Physiol 2005 ; 90 : 71–78. [CrossRef] [PubMed]
  13. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009 ; 73 : 1662–1669. [CrossRef] [PubMed]
  14. Marks WJ, Jr, Bartus RT, Siffert J, Davis CS, et al. Gene delivery of AAV2-neurturin for Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010 ; 9 : 1164–1172. [CrossRef] [PubMed]
  15. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011 ; 10 : 309–319. [CrossRef] [PubMed]
  16. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene 2013 ; 525 : 174–181. [CrossRef] [PubMed]
  17. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000 ; 290 : 767–773. [CrossRef] [PubMed]
  18. Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014 ; 383 : 1138–1146. [CrossRef] [PubMed]
  19. Miyashita T, Shao YR, Chung J, et al. Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex. Front Neural Circuits 2013 ; 7 : 8. [PubMed]
  20. Senova YS, et al. Optical stimulation of the cortico-subthalamic pathway using lentiviral vector with retrograde transport properties for CHR-2-eYFP in non-human primates. New Orleans, LA : Society for Neuroscience, 2012.
  21. Gerits A, Farivar R, Rosen BR, et al. Optogenetically induced behavioral and functional network changes in primates. Curr Biol 2012 ; 22 : 1722–1726. [CrossRef] [PubMed]
  22. Klapoetke NC, Murata Y, Kim SS, et al. Independent optical excitation of distinct neural populations. Nat Methods 2014 ; 11 : 338–346. [CrossRef] [PubMed]
  23. Lin JY, Knutsen PM, Muller A, et al. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation. Nat Neurosci 2013 ; 16 : 1499–1508. [CrossRef] [PubMed]
  24. Chuong AS, Miri ML, Busskamp V, et al. Noninvasive optical inhibition with a red-shifted microbial rhodopsin. Nat Neurosci 2014 ; 17 : 1123–1129. [CrossRef] [PubMed]
  25. Berndt A, Yizhar O, Gunaydin LA, et al. Bi-stable neural state switches. Nat Neurosci 2009 ; 12 : 229–234. [CrossRef] [PubMed]
  26. Yizhar O, Fenno LE, Prigge M, et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011 ; 477 : 171–178. [CrossRef] [PubMed]
  27. Han X., Qian X, Bernstein JG, et al. Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron 2009 ; 62 : 191–198. [CrossRef] [PubMed]
  28. Han X, Chow BY, Zhou H, et al. A high-light sensitivity optical neural silencer: development and application to optogenetic control of non-human primate cortex. Front Syst Neurosci 2011 ; 5 : 18. [PubMed]
  29. Diester I, Kaufman MT, Mogri M, et al. An optogenetic toolbox designed for primates. Nat Neurosci 2011 ; 14 : 387–397. [CrossRef] [PubMed]
  30. Cavanaugh J, Monosov IE, McAlonan K, et al. Optogenetic inactivation modifies monkey visuomotor behavior. Neuron 2012 ; 76 : 901–907. [CrossRef] [PubMed]
  31. Lang AE, Lozano AM. Parkinson’s disease. First of two parts. N Engl J Med 1998 ; 339 : 1044–1053. [CrossRef] [PubMed]
  32. Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998 ; 339 : 1130–1143. [CrossRef] [PubMed]
  33. Kravitz AV, Freeze BS, Parker PR, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature 2010 ; 466 : 622–626. [CrossRef] [PubMed]
  34. Prashanth LK, Fox S, Meissner WG. L-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol 2011 ; 98 : 31–54. [CrossRef] [PubMed]
  35. Benabid AL, Pollak P, Gross C, et al. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson’s disease. Stereotact Funct Neurosurg 1994 ; 62 : 76–84. [CrossRef] [PubMed]
  36. Carron R, Chabardes S, Hammond C. Les mécanismes d’action de la simulation cérébrale à haute fréquence. Neurochirurgie 2012 ; 58 : 209–217. [CrossRef] [PubMed]
  37. Gradinaru V, Mogri M, Thompson KR, et al. Optical deconstruction of parkinsonian neural circuitry. Science 2009 ; 324 : 354–359. [CrossRef] [PubMed]
  38. Drouot X, Oshino S, Jarraya B, et al. Functional recovery in a primate model of Parkinson’s disease following motor cortex stimulation. Neuron 2004 ; 44 : 769–778. [CrossRef] [PubMed]
  39. Lefaucheur JP, Drouot X, Von Raison F, et al. Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson’s disease. Clin Neurophysiol 2004 ; 115 : 2530–2541. [CrossRef] [PubMed]
  40. Mendes Martins V, Coste J, Derost P, et al. Complications chirurgicales de la stimulation cérébrale profonde : expérience clinique à propos de 184 cas. Neurochirurgie 2012; 58 : 219–224. [CrossRef] [PubMed]
  41. Picot MC, Baldy-Moulinier M, Daurès JP, et al. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia 2008 ; 49 : 1230–1238. [CrossRef] [PubMed]
  42. Laxpati NG, Kasoff WS, Gross RE. Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials. Neurotherapeutics 2014 ; 11 : 508–526. [CrossRef]
  43. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia 2010 ; 51 : 899–908. [CrossRef] [PubMed]
  44. Tonnesen J, Sørensen AT, Deisseroth K, et al. Optogenetic control of epileptiform activity. Proc Natl Acad Sci USA 2009 ; 106 : 12162–12167. [CrossRef]
  45. Wykes RC, Heeroma JH, Mantoan L, et al. Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med 2012; 4 : 161ra152. [CrossRef] [PubMed]
  46. Berglind F, Ledri M, Sørensen AT, et al. Optogenetic inhibition of chemically induced hypersynchronized bursting in mice. Neurobiol Dis 2014 ; 65 : 133–141. [CrossRef] [PubMed]
  47. Sukhotinsky I, Chan AM, Ahmed OJ, et al. Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS One 2013 ; 8 : e62013. [CrossRef] [PubMed]
  48. Ledri M, Madsen MG, Nikitidou L, et al. Global optogenetic activation of inhibitory interneurons during epileptiform activity. J Neurosci 2014 ; 34 : 3364–3377. [CrossRef] [PubMed]
  49. Cohen I, Navarro V, Clemenceau S, et al. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002 ; 298 : 1418–1421. [CrossRef] [PubMed]
  50. Wozny C, Kivi A, Lehmann TN, et al. Comment on: on the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2003 ; 301 : 463. [CrossRef]
  51. Paz JZ, Davidson TJ, Frechette ES, et al. Closed-loop optogenetic control of thalamus as a tool for interrupting seizures after cortical injury. Nat Neurosci 2013 ; 16 : 64–70. [CrossRef] [PubMed]
  52. Krook-Magnuson E, Armstrong C, Oijala M, Soltesz I. On-demand optogenetic control of spontaneous seizures in temporal lobe epilepsy. Nat Commun 2013 ; 4 : 1376. [CrossRef] [PubMed]
  53. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME. Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 2005 ; 11 : 177–185. [CrossRef] [PubMed]
  54. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet 2006 ; 368 : 1795–1809. [CrossRef] [PubMed]
  55. Fahim AT, Daiger SP, Weleber RG Retinitis pigmentosa overview. Seattle (WA) : GeneReviews, 2000.
  56. Maghami MH, Sodagar AM, Lashay A, et al. Visual prostheses: the enabling technology to give sight to the blind. J Ophthalmic Vis Res 2014 ; 9 : 494–505. [CrossRef] [PubMed]
  57. Humayun MS, Dorn JD, da Cruz L, et al. Interim results from the international trial of second sight’s visual prosthesis. Ophthalmology 2012 ; 119 : 779–788. [CrossRef] [PubMed]
  58. Uy HS, Chan PS, Cruz FM. Stem cell therapy: a novel approach for vision restoration in retinitis pigmentosa. Med Hypothesis Discov Innov Ophthalmol 2013 ; 2 : 52–55. [PubMed]
  59. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006 ; 6 : 717–726. [CrossRef] [PubMed]
  60. Petrs-Silva H, Linden R. Advances in gene therapy technologies to treat retinitis pigmentosa. Clin Ophthalmol 2014 ; 8 : 127–136. [PubMed]
  61. Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci 2013 ; 36 : 467–488. [CrossRef] [PubMed]
  62. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther 2013 ; 21 : 509–519. [CrossRef] [PubMed]
  63. Dalkara D, Sahel JA. Gene therapy for inherited retinal degenerations. CR Biol 2014 ; 337 : 185–192. [CrossRef]
  64. Stieger K, Cronin T, Bennett J, Rolling F. Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods Mol Biol 2011 ; 807 : 179–218. [CrossRef] [PubMed]
  65. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006 ; 50 : 23–33. [CrossRef] [PubMed]
  66. Tomita H, Sugano E, Fukazawa Y, et al. Visual properties of transgenic rats harboring the channelrhodopsin-2 gene regulated by the thy-1.2 promoter. PLoS One 2009 ; 4 : e7679. [CrossRef] [PubMed]
  67. Thyagarajan S, van Wyk M, Lehmann K, et al. Visual function in mice with photoreceptor degeneration and transgenic expression of channelrhodopsin 2 in ganglion cells. J Neurosci 2010 ; 30 : 8745–8758. [CrossRef] [PubMed]
  68. Lin B, Koizumi A, Tanaka N, et al. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. Proc Natl Acad Sci USA 2008 ; 105 : 16009–16014. [CrossRef]
  69. Caporale N, Kolstad KD, Lee T, et al. LiGluR restores visual responses in rodent models of inherited blindness. Mol Ther 2011 ; 19 : 1212–1219. [CrossRef] [PubMed]
  70. Lagali PS, Balya D, Awatramani GB, et al. Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. Nat Neurosci 2008 ; 11 : 667–675. [CrossRef] [PubMed]
  71. Cronin T., Vandenberghe LH, Hantz P, et al. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 2014 ; 6 : 1175–1190. [CrossRef] [PubMed]
  72. Mace E, Vandenberghe LH, Hantz P, et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther 2014 ; 23 : 7–16. [CrossRef] [PubMed]
  73. Doroudchi MM, Greenberg KP, Liu J, et al. Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness. Mol Ther 2011 ; 19 : 1220–1229. [CrossRef] [PubMed]
  74. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010 ; 329 : 413–417. [CrossRef] [PubMed]
  75. Reutsky-Gefen I, Golan L, Farah N, et al. Holographic optogenetic stimulation of patterned neuronal activity for vision restoration. Nat Commun 2013 ; 4 : 1509. [CrossRef] [PubMed]
  76. Nirenberg S, Pandarinath C. Retinal prosthetic strategy with the capacity to restore normal vision. Proc Natl Acad Sci USA 2012 ; 109 : 15012–15017. [CrossRef]
  77. Barrett JM, Berlinguer-Palmini R, Degenaar P. Optogenetic approaches to retinal prosthesis. Vis Neurosci 2014 ; 31 : 345–354. [CrossRef] [PubMed]
  78. Jacobson SG, Sumaroka A, Luo X, Cideciyan AV. Retinal optogenetic therapies: clinical criteria for candidacy. Clin Genet 2013 ; 84 : 175–182. [CrossRef] [PubMed]
  79. RetroSense Therapeutics. Available from: http://www.retro-sense.com/.
  80. McDevitt RA, Reed SJ, Britt JP. Optogenetics in preclinical neuroscience and psychiatry research: recent insights and potential applications. Neuropsychiatr Dis Treat 2014 ; 10 : 1369–1379. [PubMed]
  81. Eos Neuroscience. Available from: http://www.eosneuroscience.com/.
  82. GenSight Biologics. Available from: http://www.gensight-biologics.com.
  83. Circuit Therapeutics. Available from: http://circuittx.com/.
  84. Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nat Rev Neurosci 2010 ; 11 : 760–772. [CrossRef] [PubMed]
  85. Dalkara D. La conception de vecteurs adaptés à la thérapie génique oculaire. Med Sci (Paris) 2015; 31 (sous presse). [PubMed]
  86. Flores Alves Dos Santos J, Mallet L. Le trouble obsessionnel compulsif. Med Sci (Paris) 2013 ; 29 : 1111–1116. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.